[Protection of reproduction function in women with Hodgkin's disease in the course of polychemotherapy].
OBJECTIVE
To evaluate efficiency of estrogen-gestagen treatment for protection of the ovaries during polychemotherapy.


METHODS
Ultrasonography of the pelvic organs, radioimmunoassay of LH, FSH, prolactin, E2, testosterone were performed in 95 women of child-bearing age with different stages of Hodgkin's disease.


RESULTS
Cytostatic therapy of Hodgkin's disease had ovariotoxic effects and led to amenorrhea in 83% of the examinees. Regular estrogen-gestagen treatment protected ovaries in 86% of the patients.


CONCLUSIONS
It is recommended for women to take estrogen-gestagen drugs to protect ovaries during polychemotherapy of Hodgkin's disease.
Ignashina
E V
EV
Rasstrigin
N A
NA
Margolin
O V
OV
Pivnik
A V
AV
Shilin
D E
DE
D000293:Adolescent; D000328:Adult; D000568:Amenorrhea / Q000097:blood / Q000139:chemically induced / Q000517:prevention & control*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D004359:Drug Therapy, Combination; D004958:Estradiol / Q000097:blood; D004967:Estrogens / Q000627:therapeutic use*; D005260:Female; D006065:Gonadotropins, Pituitary / Q000097:blood; D006689:Hodgkin Disease / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D008875:Middle Aged; D010053:Ovary / Q000000981:diagnostic imaging / Q000187:drug effects*; D010388:Pelvis / Q000000981:diagnostic imaging; D011372:Progestins / Q000627:therapeutic use*; D011863:Radioimmunoassay; D012098:Reproduction / Q000187:drug effects; D013739:Testosterone / Q000097:blood; D014463:Ultrasonography
D004967:Estrogens; D006065:Gonadotropins, Pituitary; D011372:Progestins; D013739:Testosterone; D004958:Estradiol